# CONTENTS

<table>
<thead>
<tr>
<th>CHAPTER</th>
<th>DESCRIPTION</th>
<th>PAGE NO.</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIST OF ABBREVIATIONS</td>
<td></td>
<td>i</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td></td>
<td>ii</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td></td>
<td>iii- iv</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td></td>
<td>v</td>
</tr>
<tr>
<td>1.</td>
<td>INTRODUCTION</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Objectives of the study</td>
<td>6</td>
</tr>
<tr>
<td>2.</td>
<td>REVIEW OF LITERATURE</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>2.1 Characterization of CYP26 family member.</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>2.2 Molecular and physiological function of CYP26</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2.3 Retinoic acid metabolizing enzyme CYP26A1 and its role in human cancer.</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>2.4 Mutation of CYP26A1 in humans</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>2.5 Study of drug-retinoid interactions.</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>2.6 Inhibition of the catalytic activity of CYP26A1 by specific compounds.</td>
<td>20</td>
</tr>
<tr>
<td>3.</td>
<td>MATERIALS AND METHODS</td>
<td>22</td>
</tr>
<tr>
<td></td>
<td>3.1 Materials</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td>3.2 Methodology</td>
<td>27</td>
</tr>
<tr>
<td></td>
<td>3.2.1 Identification of target protein CYP26A1 using \textit{in silico} proteome analysis</td>
<td>30</td>
</tr>
<tr>
<td></td>
<td>3.2.2 Structure prediction and validation of target protein CYP26A1</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>3.2.3 Virtual screening of modeled target protein CYP26A1 against literature driven drug library</td>
<td>36</td>
</tr>
<tr>
<td></td>
<td>3.2.4 Protein-ligand interaction through docking</td>
<td>38</td>
</tr>
<tr>
<td></td>
<td>3.2.5 Evaluation of drug potency as CYP26A1 inhibitor</td>
<td></td>
</tr>
</tbody>
</table>

Contd..
<table>
<thead>
<tr>
<th>4.</th>
<th>RESULTS AND DISCUSSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>Identification and analysis of target protein CYP26A1</td>
</tr>
<tr>
<td>4.2</td>
<td>Analysis of structure prediction and validation of target protein</td>
</tr>
<tr>
<td>4.3</td>
<td>Analysis of virtual screening of modeled target protein CYP26A1 against literature driven drug library</td>
</tr>
<tr>
<td>4.4</td>
<td>Analysis of protein-ligand interaction through docking</td>
</tr>
<tr>
<td>4.5</td>
<td>Evaluation of drug potency</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5.</th>
<th>SUMMARY AND CONCLUSION</th>
</tr>
</thead>
</table>

| REFERENCES | |
| APPENDICES | vi-xii |
| PUBLISHED RESEARCH PAPERS | |